Drugs / ADO09
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03916640 | Jan → Mar 2019 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03981627 | Jun 2019 → Jun 2020 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2021-09-21 | Adocia | Results ADOCIA announces Oral Presentation Reviewing M1Pram (ADO09) at the occasion of the 57th Annual Meeting of EASD adocia.com ↗
On this occasion, Adocia will be presenting Parts A and B of the Proof-of-Concept Phase I clinical trial with M1Pram, a co-formulation of pramlintide and insulin A21G that improves post-prandial glucose and body weight versus insulin aspart in type 1 diabetes. |
| 2021-06-02 | Adocia | Results ADOCIA Presents Clinical Results on M1Pram at the 14th International Conference on ATTD 2021 adocia.com ↗
ADO09, A CO-FORMULATION OF PRAMLINTIDE AND INSULIN A21G IMPROVES POST-PRANDIAL GLUCOSE (PPG) VERSUS INSULIN ASPART IN TYPE 1 DIABETES (T1D) |
| 2020-09-15 | Adocia | Results Adocia announces Positive Topline Results of Phase 1b Study for M1Pram in People with type 1 Diabetes. adocia.com ↗ |
| 2020-06-08 | Adocia | Results Adocia Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 80th Scientific Sessions – Virtual experience adocia.com ↗
In this study, M1Pram offered better glycemic control with less insulin consumption and also significant weight loss. |
| 2020-04-23 | Adocia | Results Adocia announces positive topline results of the exploratory Phase 1b study of ADO09 (M1Pram) in people with type 1 diabetes adocia.com ↗
Adocia announces positive topline results of the exploratory Phase 1b study of ADO09 (M1Pram) in people with type 1 diabetes |
| 2019-09-10 | Adocia | Results Adocia Announces Oral Presentation Covering ADO09, its pramlintide insulin coformulation, at EASD adocia.com ↗
ADO09, a co-formulation of the amylin-analog pramlintide and the A21G human insulin analog, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes |
| 2019-04-10 | Adocia | Results Adocia announces topline results for the first clinical study of ADO09, a new co-formulation of pramlintide and a prandial insulin adocia.com ↗
ADO09 showed similar glucose control over the first two hours after a meal compared to separate injections of Symlin® and Humulin® |
All press releases naming this drug 8 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADO09 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03981627 ↗ |
| Route | Subcutaneous | “Subcutaneous injection of ADO09 formulation” NCT03916640 ↗ |